SPX -0.09% VIX 0.50%
DOW INDUSTRIALS DOWN 130 POINTS AS THURSDAY STOCK-MARKET DECLINES STEEPEN 
FOR THE DOW EARLY THURSDAY, IBM AND UNITEDHEALTH ARE EQUAL, OPPOSING FORCES 
U.S. STOCKS ON TRACK THURSDAY MORNING FOR THIRD STRAIGHT DOWN DAY 
PHILLY FED MANUFACTURING GAUGE REBOUNDS IN JULY 
OIL PRICES RISE OFF 2-WEEK LOWS AS IRAN SEIZES TANKER, LEVELS SMUGGLING CHARGE 
SCHUMER ASKS FBI TO INVESTIGATE FACEAPPS POTENTIAL KREMLIN TIES 
U.S. FIRST-TIME UNEMPLOYMENT CLAIMS ON RISE IN MID-JULY 
APPLE UPGRADE BY RAYMOND JAMES CITES 5G IPHONE PROSPECTS 
NEED TO KNOW: ENERGY STOCKS COULD DOUBLE BY NEXT SUMMER, SAYS CONTRARIAN 
EFFORT TO REDUCE NO-SHOWS FOR CFA EXAM FALLING SHORT: FINANCIAL NEWS 
Thu, Jul 18 1:21pm


Alexion Pharmaceuticals Inc [ALXN]
$122.24 1.18 (0.95%)

ALXN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 27.09 Billion
ALXN Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.


Visit Website

ALXN Earnings

EPS 2.63 P/E Ratio 392.83
Previous Earnings Thu, Apr 25, 2019
Latest Earnings Wed, Jul 24, 2019 (In 6 days)

ALXN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALXN Charts

$92.56
52 Week Range
$141.86
Dec 24, 2018
Apr 10, 2019



Symbol Price Day % YTD %
ALXN $122.24 -0.95% 24.62%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy